Susanne Eder1, Johannes Leierer1, Julia Kerschbaum1, Laszlo Rosivall2, Andrzej Wiecek3, Dick de Zeeuw4, Patrick B Mark5, Georg Heinze6, Peter Rossing7, Hiddo L Heerspink4, Gert Mayer1. 1. Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria. 2. International Nephrology Research and Training Center, Institute of Pathophysiology, Semmelweis University, Budapest, Hungary. 3. Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland. 4. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 5. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom. 6. Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University Vienna, Vienna, Austria. 7. Novo Nordisk Foundation Center for Basic Metabolic Research, Metabolism Center, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND/AIMS: The prevalence of diabetes mellitus type 2 and kidney disease in these patients varies widely between European countries. METHODS: In addition to store bio-samples the "Prospective cohort study in patients with type 2 diabetes mellitus for validation of biomarkers" collects information on history, physical status, laboratory measurements and medication in 4000 patients with diabetes mellitus type 2, being taken care of at the primary level of healthcare in 5 European countries (Austria, Hungary, Netherlands, Poland and Scotland). Next to comparing the rate of loss of eGFR between the countries, a further objective of the PROVALID study is to determine the 5-year cumulative incidence of renal and cardiovascular outcomes. RESULTS: The mean age of the population recruited is 62.9±10 years, 54.6% are male and the mean BMI is 30.9±5.4 kg/m2. Metabolic control (median HBA1c 6.8 % (6.2; 7.5)) is achieved via administration of metformin in 67.4% of the patients and insulin in 30.3%. Median systolic and diastolic blood pressure at recruitment is 135 (125; 146) and 80 (72; 85) mmHg, 65.4% of subjects received RAAS blocking agents. Mean eGFR is 80.7±29.2 ml/min/1.73m2 and median baseline albumin/creatinine ratio 8.3 mg (IQR: 3.8 and 25.1). CONCLUSION: PROVALID will provide information on incidence and progression of renal and cardiovascular disease and therapy in patients with type 2 diabetes mellitus in different European countries. Thus, in contrast to many other cohort studies we will be able to associate national clinical practise pattern with outcome in this highly vulnerable patient population.
BACKGROUND/AIMS: The prevalence of diabetes mellitus type 2 and kidney disease in these patients varies widely between European countries. METHODS: In addition to store bio-samples the "Prospective cohort study in patients with type 2 diabetes mellitus for validation of biomarkers" collects information on history, physical status, laboratory measurements and medication in 4000 patients with diabetes mellitus type 2, being taken care of at the primary level of healthcare in 5 European countries (Austria, Hungary, Netherlands, Poland and Scotland). Next to comparing the rate of loss of eGFR between the countries, a further objective of the PROVALID study is to determine the 5-year cumulative incidence of renal and cardiovascular outcomes. RESULTS: The mean age of the population recruited is 62.9±10 years, 54.6% are male and the mean BMI is 30.9±5.4 kg/m2. Metabolic control (median HBA1c 6.8 % (6.2; 7.5)) is achieved via administration of metformin in 67.4% of the patients and insulin in 30.3%. Median systolic and diastolic blood pressure at recruitment is 135 (125; 146) and 80 (72; 85) mmHg, 65.4% of subjects received RAAS blocking agents. Mean eGFR is 80.7±29.2 ml/min/1.73m2 and median baseline albumin/creatinine ratio 8.3 mg (IQR: 3.8 and 25.1). CONCLUSION: PROVALID will provide information on incidence and progression of renal and cardiovascular disease and therapy in patients with type 2 diabetes mellitus in different European countries. Thus, in contrast to many other cohort studies we will be able to associate national clinical practise pattern with outcome in this highly vulnerable patient population.
Authors: Andreas Heinzel; Michael Kammer; Gert Mayer; Roman Reindl-Schwaighofer; Karin Hu; Paul Perco; Susanne Eder; Laszlo Rosivall; Patrick B Mark; Wenjun Ju; Matthias Kretzler; Peter Gilmour; Jonathan M Wilson; Kevin L Duffin; Moustafa Abdalla; Mark I McCarthy; Georg Heinze; Hiddo L Heerspink; Andrzej Wiecek; Maria F Gomez; Rainer Oberbauer Journal: Diabetes Care Date: 2018-07-06 Impact factor: 19.112
Authors: Megumi Oshima; Brendon L Neuen; JingWei Li; Vlado Perkovic; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Adeera Levin; Kenneth W Mahaffey; Luca De Nicola; Carol Pollock; Norman Rosenthal; David C Wheeler; Meg J Jardine; Hiddo J L Heerspink Journal: J Am Soc Nephrol Date: 2020-09-30 Impact factor: 10.121
Authors: Kim M Gooding; Chrysta Lienczewski; Massimo Papale; Niina Koivuviita; Marlena Maziarz; Anna-Maria Dutius Andersson; Kanishka Sharma; Paola Pontrelli; Alberto Garcia Hernandez; Julie Bailey; Kay Tobin; Virva Saunavaara; Anna Zetterqvist; David Shelley; Irvin Teh; Claire Ball; Sapna Puppala; Mark Ibberson; Anil Karihaloo; Kaj Metsärinne; Rosamonde E Banks; Peter S Gilmour; Michael Mansfield; Mark Gilchrist; Dick de Zeeuw; Hiddo J L Heerspink; Pirjo Nuutila; Matthias Kretzler; Matthew Welberry Smith; Loreto Gesualdo; Dennis Andress; Nicolas Grenier; Angela C Shore; Maria F Gomez; Steven Sourbron Journal: BMC Nephrol Date: 2020-06-29 Impact factor: 2.388
Authors: Julia Kerschbaum; Michael Rudnicki; Alexander Dzien; Christine Dzien-Bischinger; Hannes Winner; Hiddo Lambers Heerspink; László Rosivall; Andrzej Wiecek; Patrick B Mark; Susanne Eder; Sara Denicolò; Gert Mayer Journal: Sci Rep Date: 2020-11-12 Impact factor: 4.379
Authors: Carolin Huber; Martin Krauss; Vera Reinstadler; Sara Denicolò; Gert Mayer; Tobias Schulze; Werner Brack; Herbert Oberacher Journal: Anal Bioanal Chem Date: 2022-01-26 Impact factor: 4.142
Authors: Sara Denicolò; Verena Vogi; Felix Keller; Stefanie Thöni; Susanne Eder; Hiddo J L Heerspink; László Rosivall; Andrzej Wiecek; Patrick B Mark; Paul Perco; Johannes Leierer; Andreas Kronbichler; Marion Steger; Simon Schwendinger; Johannes Zschocke; Gert Mayer; Emina Jukic Journal: Kidney Int Rep Date: 2022-02-03